বাংলায় দেখুন
Linzolid

Linzolid

Powder for Suspension

🧬 Linezolid 🏢 Incepta Pharmaceuticals Ltd.
Generic Name Linezolid
Manufacturer Incepta Pharmaceuticals Ltd.
Unit Price 100 ml bottle: ৳ 280.00

🔹 Indications

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Pharmacology

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Dosage & Administration

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Interaction

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Contraindications

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Side Effects

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Pregnancy & Lactation

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

🔹 Precautions & Warnings

Linzolid is indicated for the treatment of:
  • Nosocomial pneumonia
  • Community-acquired pneumonia
  • Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis
  • Uncomplicated skin and skin structure infections
  • Vancomycin-resistant Enterococcus faecium infections
Limitations of use: Linzolid is not indicated for the treatment of Gram-negative infections. The safety and efficacy of Linzolid given for longer than 28 days have not been evaluated in controlled clinical trials.

💡 Frequently Asked Questions

Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...
Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...
Linzolid is indicated for the treatment of: Nosocomial pneumonia Community-acquired pneumonia Complicated skin and skin structure infection including diabetic foot infections, without concomitant osteomyelitis Uncomplicated skin and skin structure i...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review